Coming Together to Make a Difference
ARC held its biannual Industry Advisory Council meeting in Boston on March 27th, 2017. The day-long meeting was attended by representatives from pharmaceutical and biotech companies developing new treatments for amyloidosis. This provided a unique opportunity for these companies to unite and develop partnerships of mutual interest.
Part of ARC’s strategy is to foster cross-company conversations in order to identify areas of resource-wasting replication. Precompetitive research, educational awareness programs, and developing a streamlined strategy are primary focal points.
Joining us were the following companies that all have drugs in clinical trials for amyloidosis.
- Alnylam
- GSK
- Ionis
- Janssen
- Pfizer
- Prothena
- Takeda
We were delighted to welcome two new companies to the council for the first time that have products in early stage development.
- Caelum
- Intellia
At the meeting the following areas were prioritized:
- Market access
- Epidemiology
- Awareness
- Early detection/diagnosis
- Clinical endpoints and QOL/PROs
Participating companies will be partnering with ARC to develop strategies and launch work streams to address them. We look forward to sharing more details on these key areas in the near future.
- Categories
- Lastest Posts
- FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
- ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care
- The More Things Change, the More They Stay the Same
- The Inflation Reduction Act: The Devil is in the Details for Patients with Rare Diseases
